301230 Stock Overview
Operates as a CRO, CDMO, and CMO service provider of drug discovery in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
PharmaResources (Shanghai) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.07 |
| 52 Week High | CN¥42.30 |
| 52 Week Low | CN¥16.28 |
| Beta | 1.06 |
| 1 Month Change | 7.67% |
| 3 Month Change | 49.39% |
| 1 Year Change | 4.32% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -0.28% |
Recent News & Updates
Shareholder Returns
| 301230 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 4.0% | -1.5% | -1.2% |
| 1Y | 4.3% | -18.1% | 11.8% |
Return vs Industry: 301230 exceeded the CN Life Sciences industry which returned -18.1% over the past year.
Return vs Market: 301230 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 301230 volatility | |
|---|---|
| 301230 Average Weekly Movement | 11.0% |
| Life Sciences Industry Average Movement | 10.1% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 301230's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 301230's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 1,012 | Ping Chen | www.pharmaresources.cn |
PharmaResources (Shanghai) Co., Ltd. operates as a CRO, CDMO, and CMO service provider of drug discovery in China. It also manufactures APIs and key intermediates. The company offers preclinical services.
PharmaResources (Shanghai) Co., Ltd. Fundamentals Summary
| 301230 fundamental statistics | |
|---|---|
| Market cap | CN¥3.86b |
| Earnings (TTM) | CN¥6.93m |
| Revenue (TTM) | CN¥513.91m |
557.2x
P/E Ratio7.5x
P/S RatioIs 301230 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301230 income statement (TTM) | |
|---|---|
| Revenue | CN¥513.91m |
| Cost of Revenue | CN¥408.91m |
| Gross Profit | CN¥105.00m |
| Other Expenses | CN¥98.07m |
| Earnings | CN¥6.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.05 |
| Gross Margin | 20.43% |
| Net Profit Margin | 1.35% |
| Debt/Equity Ratio | 1.2% |
How did 301230 perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield709%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 11:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PharmaResources (Shanghai) Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |